Trupanion (TRUP) Expected to Announce Earnings on Thursday

Trupanion (NASDAQ:TRUP) is expected to announce its Q1 2025 earnings results after the market closes on Thursday, May 1st. Analysts expect Trupanion to post earnings of ($0.05) per share and revenue of $337.81 million for the quarter.

Trupanion (NASDAQ:TRUP) last posted its quarterly earnings data on Wednesday, February 19th. The financial services provider reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.06 by ($0.02). Trupanion had a negative net margin of 0.75% and a negative return on equity of 3.08%. The business had revenue of $337.31 million for the quarter, compared to the consensus estimate of $335.41 million. On average, analysts expect Trupanion to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Trupanion Stock Up 2.0 %

NASDAQ TRUP opened at $35.68 on Thursday. Trupanion has a 12 month low of $19.69 and a 12 month high of $57.90. The company has a market capitalization of $1.52 billion, a P/E ratio of -155.13, a PEG ratio of 6.02 and a beta of 1.66. The company’s 50 day simple moving average is $35.90 and its 200 day simple moving average is $45.38. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.71 and a quick ratio of 1.66.

Insider Buying and Selling

In other Trupanion news, SVP Emily Dreyer sold 14,025 shares of the firm’s stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $32.41, for a total transaction of $454,550.25. Following the completion of the sale, the senior vice president now directly owns 27,645 shares in the company, valued at approximately $895,974.45. This trade represents a 33.66 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Margaret Tooth sold 4,000 shares of Trupanion stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $37.17, for a total value of $148,680.00. Following the transaction, the chief executive officer now directly owns 118,784 shares in the company, valued at approximately $4,415,201.28. This trade represents a 3.26 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 33,792 shares of company stock valued at $1,122,802. Company insiders own 5.50% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Stifel Nicolaus reduced their price objective on Trupanion from $44.00 to $41.00 and set a “hold” rating for the company in a research note on Thursday, February 20th. Piper Sandler reduced their target price on Trupanion from $57.00 to $52.00 and set an “overweight” rating for the company in a report on Thursday, February 20th. Two research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $46.60.

About Trupanion

Trupanion, Inc, together with its subsidiaries, provides medical insurance for cats and dogs on a monthly subscription basis in the United States, Canada, Continental Europe, and Australia. The company operates in two segments, Subscription Business and Other Business. It serves pet owners and veterinarians.